[{"arm_notes": "", "treatment_id": null, "treatment_name": "Clinical safety/efficacy; randomized; double-blinded; phase 2 trial of placebo versus BLD-2660. It will be included 120 patients of both sexes aged 18 years or older. Control group: 40 patients will take placebo orally twice a day for 10 days; while hospitalized. Experimental group: 80 patients will take BLD-2660 900mg orally twice a day for 10 days; while hospitalized or until they reach any of the protocol discontinuation criteria; i.e: pregnancy; consent withdrawal; hospital discharge or adverse event that justifies the patient withdrawal or study termination by the sponsor;Drug;E02.319.267.100;D27.505.954.122.388", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 212, "treatment_name": "Bld-2660", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Clinical safety/efficacy; randomized; double-blinded; phase 2 trial of placebo versus BLD-2660. It will be included 120 patients of both sexes aged 18 years or older. Control group: 40 patients will take placebo orally twice a day for 10 days; while hospitalized. Experimental group: 80 patients will take BLD-2660 900mg orally twice a day for 10 days; while hospitalized or until they reach any of the protocol discontinuation criteria; i.e: pregnancy; consent withdrawal; hospital discharge or adverse event that justifies the patient withdrawal or study termination by the sponsor;Drug;E02.319.267.100;D27.505.954.122.388", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Clinical safety/efficacy; randomized; double-blinded; phase 2 trial of placebo versus BLD-2660. It will be included 120 patients of both sexes aged 18 years or older. Control group: 40 patients will take placebo orally twice a day for 10 days; while hospitalized. Experimental group: 80 patients will take BLD-2660 900mg orally twice a day for 10 days; while hospitalized or until they reach any of the protocol discontinuation criteria; i.e: pregnancy; consent withdrawal; hospital discharge or adverse event that justifies the patient withdrawal or study termination by the sponsor;Drug;Administration; Oral;Antiviral Agents", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]